Treatment of Tardive Dyskinesia with Clonazepam: A Case Report

Overview

Journal Clin Case Rep

Date 2024 May 15

PMID 38745734

Authors

Bikram Chhetri

Dawa Gyeltshen

Affiliations

Soon will be listed here.

Abstract

Clonazepam has some evidence in the treatment of tardive dyskinesia. It can be used as an alternative treatment option in situations where vesicular monoamine transporter 2 inhibitors are not available or when it is not feasible to use them.

Citing Articles

Treatment of tardive dyskinesia with clonazepam: A case report.

Chhetri B, Gyeltshen D Clin Case Rep. 2024; 12(5):e8951.

PMID: 38745734 PMC: 11091010. DOI: 10.1002/ccr3.8951.

References

Bashir H, Jankovic J . Treatment of Tardive Dyskinesia. Neurol Clin. 2020; 38(2):379-396. DOI: 10.1016/j.ncl.2020.01.004. View

Arat-Celik H, Kok-Kendirlioglu B, Cetin B, Kucukgoncu S . Double-Edged Sword: A Case with Withdrawal-Emergent Dyskinesia. Turk Psikiyatri Derg. 2021; 32(4):283-285. DOI: 10.5080/u25613. View

Cornett E, Novitch M, Kaye A, Kata V, Kaye A . Medication-Induced Tardive Dyskinesia: A Review and Update. Ochsner J. 2017; 17(2):162-174. PMC: 5472076. View

Lerner P, Miodownik C, Lerner V . Tardive dyskinesia (syndrome): Current concept and modern approaches to its management. Psychiatry Clin Neurosci. 2015; 69(6):321-34. DOI: 10.1111/pcn.12270. View

Mohapatra S . Successful Management of Tardive Dyskinesia with Quetiapine and Clonazepam in a Patient of Schizophrenia with Type 2 Diabetes Mellitus. Clin Psychopharmacol Neurosci. 2016; 14(2):218-20. PMC: 4857859. DOI: 10.9758/cpn.2016.14.2.218. View

Caroff S, Ungvari G, Cunningham Owens D . Historical perspectives on tardive dyskinesia. J Neurol Sci. 2018; 389:4-9. DOI: 10.1016/j.jns.2018.02.015. View

Lin C, Ondo W . Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia. J Neurol Sci. 2018; 389:48-54. DOI: 10.1016/j.jns.2018.02.014. View

Solmi M, Pigato G, Kane J, Correll C . Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018; 12:1215-1238. PMC: 5958944. DOI: 10.2147/DDDT.S133205. View

Carbon M, Kane J, Leucht S, Correll C . Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018; 17(3):330-340. PMC: 6127753. DOI: 10.1002/wps.20579. View

10.

Arya D, Khan T, Margolius A, Fernandez H . Tardive Dyskinesia: Treatment Update. Curr Neurol Neurosci Rep. 2019; 19(9):69. DOI: 10.1007/s11910-019-0976-1. View

11.

Ricciardi L, Pringsheim T, Barnes T, Martino D, Gardner D, Remington G . Treatment Recommendations for Tardive Dyskinesia. Can J Psychiatry. 2019; 64(6):388-399. PMC: 6591749. DOI: 10.1177/0706743719828968. View

12.

Chhetri B, Gyeltshen D . Treatment of tardive dyskinesia with clonazepam: A case report. Clin Case Rep. 2024; 12(5):e8951. PMC: 11091010. DOI: 10.1002/ccr3.8951. View

13.

Caroff S . Recent Advances in the Pharmacology of Tardive Dyskinesia. Clin Psychopharmacol Neurosci. 2020; 18(4):493-506. PMC: 7609206. DOI: 10.9758/cpn.2020.18.4.493. View

14.

Bergman H, Bhoopathi P, Soares-Weiser K . Benzodiazepines for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018; 1:CD000205. PMC: 6491128. DOI: 10.1002/14651858.CD000205.pub3. View

15.

Alblowi M, Alosaimi F . Tardive dyskinesia occurring in a young woman after withdrawal of an atypical antipsychotic drug. Neurosciences (Riyadh). 2015; 20(4):376-9. PMC: 4727629. DOI: 10.17712/nsj.2015.4.20150078. View

16.

Frei K . Tardive dyskinesia: Who gets it and why. Parkinsonism Relat Disord. 2018; 59:151-154. DOI: 10.1016/j.parkreldis.2018.11.017. View